COVID-19 and Cancer Consortium Registry (CCC19)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04354701|
Recruitment Status : Recruiting
First Posted : April 21, 2020
Last Update Posted : September 9, 2021
|Condition or disease||Intervention/treatment|
|COVID-19 Invasive Malignancy (Any Type)||Other: Web-based REDCap survey|
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate hypothesis-generating and hypothesis-supporting findings that are generalizable to the population at large. Specifically:
I. Characterize patient factors, such as pre-existing comorbidities, baseline medication exposures, cancer type, status, and treatment, and demographic factors that are associated with short- and long-term outcomes of COVID-19 (laboratory-confirmed or presumptive), including severity and fatality, in patients with cancer.
II. Describe cancer treatment modifications made in response to COVID-19, including dose adjustments, changes in symptom management, or temporary or permanent cessation.
III. Evaluate the association of COVID-19 with cancer outcomes.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||15000 participants|
|Target Follow-Up Duration:||36 Months|
|Official Title:||The COVID-19 and Cancer Consortium (CCC19) Registry|
|Actual Study Start Date :||March 17, 2020|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2022|
- Other: Web-based REDCap survey
The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
- Web-based REDCap survey [ Time Frame: Approximately 18 months ]The survey includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04354701
|Contact: Vanderbilt-Ingram Service for Timely Accessemail@example.com|
|United States, Tennessee|
|Vanderbilt University Medical Center||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Sanjay Mishra, PhD 615-875-8775 firstname.lastname@example.org|
|Principal Investigator: Jeremy Warner, MD|
|Principal Investigator:||Jeremy Warner, MD||Vanderbilt-Ingram Cancer Center|